Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis

NCT05976802 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: High dose budesonide rectal foam
DRUG: Low dose budesonide rectal foam
DRUG: Matching placebo rectal foam

Sponsor

Bausch Health Americas, Inc.